clemastine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345»
  • ||||||||||  clemastine / Generic mfg.
    Trial completion date, Trial primary completion date:  RESTORE: Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis (clinicaltrials.gov) -  Nov 15, 2024   
    P3,  N=80, Recruiting, 
    Finally, CLM pretreatment protected against acute kidney injury by preventing TLR-4/ p-P38 pathway-mediated apoptotic cell death in rats. Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: May 2024 --> Dec 2027
  • ||||||||||  Tavegil (clemastine) / GSK
    Journal:  Exploring therapeutic approaches against Naegleria fowleri infections through the COVID box. (Pubmed Central) -  Aug 8, 2024   
    From these compounds, terconazole, clemastine, ABT-239 and PD-144418 showed a higher selectivity against the parasite compared to the remaining products...Assessment of mitochondrial membrane potential disruption and a significant reduction in ATP production emphasized the impact of these compounds on the mitochondria, with the identification of increased ROS production underscoring their potential as effective treatment options. This study emphasizes the potential of the mentioned COVID Box compounds against N. fowleri, providing a path for enhanced PAM therapies.
  • ||||||||||  Tavegil (clemastine) / GSK
    Preclinical, Journal:  Clemastine improves emotional and social deficits in adolescent social isolation mice by reversing demyelination. (Pubmed Central) -  Jul 28, 2024   
    More importantly, clemastine was sufficient to rescue the impairment of emotional and social memory by promoting remyelination. These findings reveal the demyelination mechanism of emotional and social deficits caused by social isolation stress in adolescence, and provides potential therapeutic targets for treating stress-related mental disorders.
  • ||||||||||  Tavegil (clemastine) / GSK
    Preclinical, Journal:  Promyelinating drugs ameliorate oligodendrocyte pathologies in a mouse model of Krabbe disease. (Pubmed Central) -  Jul 3, 2024   
    However, while Sob-AM2 showed higher efficacy in restoring the impaired differentiation and maturation of twi OLs, clemastine more potently reduced the endogenous psychosine levels. These results present the first preclinical in vitro data, suggesting that clemastine and Sob-AM2 can act directly and distinctly on OLs in KD and ameliorate their cellular pathologies associated with myelin degeneration.
  • ||||||||||  Tavegil (clemastine) / GSK
    Trial initiation date:  Clemastine Treatment in Individuals With Williams Syndrome (clinicaltrials.gov) -  May 6, 2024   
    P3,  N=30, Recruiting, 
    Our findings also underscore the potential of remyelinating therapies for TBI. Initiation date: Jan 2024 --> Apr 2024
  • ||||||||||  Tavegil (clemastine) / GSK
    Journal:  Prolonged myelin deficits contribute to neuron loss and functional impairments after ischaemic stroke. (Pubmed Central) -  Apr 8, 2024   
    Conversely, enhancing remyelination by M1R cKO or treating the pro-myelination drug clemastine after tMCAO preserves white matter integrity and neuronal survival, and accelerates functional recovery. Together, our findings demonstrate that enhancing myelinogenesis is a promising strategy to preserve neurons and promote functional recovery after ischemic stroke.
  • ||||||||||  Tavegil (clemastine) / GSK
    Preclinical, Journal:  Neuronal deletion of Gtf2i results in developmental microglial alterations in a mouse model related to Williams syndrome. (Pubmed Central) -  Mar 7, 2024   
    Lastly, systemic injection of clemastine to P4 Gtf2i cKO and control mice until P30, led to a significant interaction between genotypes and treatments on the expression levels of the phagocytic marker CD68, and a significant reduction of the macrophage/microglial marker Iba1 transcript levels in the cortex of the Gtf2i cKO treated mice. Our data thus implicate microglia as important players in WS, and that early postnatal manipulation of microglia might be beneficial in treating inflammatory and myelin-related pathologies.
  • ||||||||||  Tavegil (clemastine) / GSK
    Journal:  Clemastine/tamoxifen hybrids as easily accessible antileishmanial drug leads. (Pubmed Central) -  Feb 8, 2024   
    Two of them were identified as the potential templates for lead optimization of this series having shown the highest activities against all species in both stages of parasite. The present findings can serve as a good starting point in the search for novel antileishmanial compounds that are easy to access and highly active.
  • ||||||||||  Tavegil (clemastine) / GSK
    Symptomatic and Mechanism-Based Treatments for Neuropsychiatric Symptoms in Williams Syndrome (Gramercy (Sheraton New York Times Square Hotel); In-person) -  Sep 30, 2023 - Abstract #AACAP2023AACAP_634;    
    By promoting myelin repair, clemastine has been shown to repair myelin deficits and abnormal motor and social symptoms in mice with WS. A study with clemastine in humans with WS is now underway and will be described.
  • ||||||||||  Tavegil (clemastine) / GSK
    Journal:  Repurposing Clemastine to Target Glioblastoma Cell Stemness. (Pubmed Central) -  Sep 28, 2023   
    Finally, we showed that a neural stem cell-derived mouse glioma model displaying predominantly proneural features was similarly susceptible to clemastine treatment. Collectively, these results identify pathways essential for maintaining the stemness and progenitor features of GBMs, uncover BTIC dependency on EBP, and suggest that non-oncology, low-toxicity drugs with OPC differentiation-promoting activity can be repurposed to target GBM stemness and aid in their treatment.
  • ||||||||||  Tavegil (clemastine) / GSK
    Enrollment open:  ReVIVE: Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy (clinicaltrials.gov) -  Sep 21, 2023   
    P1/2,  N=74, Recruiting, 
    Collectively, these results identify pathways essential for maintaining the stemness and progenitor features of GBMs, uncover BTIC dependency on EBP, and suggest that non-oncology, low-toxicity drugs with OPC differentiation-promoting activity can be repurposed to target GBM stemness and aid in their treatment. Not yet recruiting --> Recruiting
  • ||||||||||  Tavegil (clemastine) / GSK
    Post general anesthesia induction anaphylaxis - Caught off guard no more (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_5914;    
    We administered fentanyl, lidocaine, propofol and rocuronium...We administered O2 100%, epinephrin, hydrocortisone, clemastine and crystalloids...Tryptase blood levels were measured within the first hour and 24h after. The allergologic investigation revealed alllergies to rocuronium and latex.
  • ||||||||||  Tavegil (clemastine) / GSK
    Preclinical, Journal:  Clemastine fumarate attenuates tauopathy and meliorates cognition in hTau mice via autophagy enhancement. (Pubmed Central) -  Jul 26, 2023   
    Notably, after administration of chloroquine, levels of Tau protein were significantly increased. When clemastine fumarate was co-administered with chloroquine, the protective effects were reversed, indicating that clemastine fumarate indeed triggered autophagy and promoted the degradation of Tau protein, while also inhibiting further Tauopathy-related neuroinflammation and synapse loss to improve cognitive function in hTau mice.